Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply
| Errataetall: |
CommentOn: Lancet Oncol. 2022 May;23(5):659-670. - PMID 35427471 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
The Lancet. Oncology - 23(2022), 6 vom: 21. Juni, Seite e246 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
André, Thierry [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.06.2022 Date Revised 22.06.2022 published: Print CommentOn: Lancet Oncol. 2022 May;23(5):659-670. - PMID 35427471 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1470-2045(22)00299-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341760323 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341760323 | ||
| 003 | DE-627 | ||
| 005 | 20231226012522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(22)00299-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341760323 | ||
| 035 | |a (NLM)35654063 | ||
| 035 | |a (PII)S1470-2045(22)00299-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a André, Thierry |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.06.2022 | ||
| 500 | |a Date Revised 22.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Lancet Oncol. 2022 May;23(5):659-670. - PMID 35427471 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Diaz, Luis A |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Shiu, Kai-Keen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Oncology |d 2000 |g 23(2022), 6 vom: 21. Juni, Seite e246 |w (DE-627)NLM117859516 |x 1474-5488 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:6 |g day:21 |g month:06 |g pages:e246 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(22)00299-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 6 |b 21 |c 06 |h e246 | ||